{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:56:32Z","timestamp":1774403792489,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Science Fund for Distinguished Young Scholars","award":["2024JJ2090"],"award-info":[{"award-number":["2024JJ2090"]}]},{"name":"Hunan Provincial Science Fund for Distinguished Young Scholars","award":["2024JJ2094"],"award-info":[{"award-number":["2024JJ2094"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272907"],"award-info":[{"award-number":["82272907"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974397"],"award-info":[{"award-number":["81974397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170789"],"award-info":[{"award-number":["82170789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Big Data System Construction Project Fund of Xiangya Hospital","award":["33020125030"],"award-info":[{"award-number":["33020125030"]}]},{"name":"Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases","award":["2023LNJJ13"],"award-info":[{"award-number":["2023LNJJ13"]}]},{"name":"Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases","award":["2022LNJJ13"],"award-info":[{"award-number":["2022LNJJ13"]}]},{"name":"Xiangya Famous Doctor Fund of Central South University","award":["33020123007"],"award-info":[{"award-number":["33020123007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07652-x","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:32:10Z","timestamp":1763944330000},"page":"3007-3022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early prediction of response to ADT plus ARPIs in mHSPC using interpretable machine learning on PSMA PET\/CT: a real-world study"],"prefix":"10.1007","volume":"53","author":[{"given":"Yinzhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiquan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-2064","authenticated-orcid":false,"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"2","key":"7652_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.euo.2023.07.014","volume":"7","author":"P Sutera","year":"2024","unstructured":"Sutera P, Shetty AC, Song Y, et al. Identification of a predictive genomic biomarker for prostate-directed therapy in synchronous low-volume metastatic castration-sensitive prostate cancer. Eur Urol Oncol. 2024;7(2):241\u20137. https:\/\/doi.org\/10.1016\/j.euo.2023.07.014.","journal-title":"Eur Urol Oncol"},{"key":"7652_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115110","volume":"213","author":"HV Stroomberg","year":"2024","unstructured":"Stroomberg HV, Helgstrand JT, Brasso K, Larsen SB, R\u00f8der A. Epidemiology of men with synchronous metastatic prostate cancer diagnosis - a nationwide 26-year temporal analysis. Eur J Cancer Oxf Engl 1990. 2024;213:115110. https:\/\/doi.org\/10.1016\/j.ejca.2024.115110.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"7652_CR3","doi-asserted-by":"publisher","unstructured":"Finianos A, Gupta K, Clark B, Simmens SJ, Aragon-Ching JB. Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. Clin Genitourin Cancer. Published online August 31, 2017:S1558\u20137673(17)30247\u20131. https:\/\/doi.org\/10.1016\/j.clgc.2017.08.006","DOI":"10.1016\/j.clgc.2017.08.006"},{"key":"7652_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.05.002","author":"Z Wang","year":"2025","unstructured":"Wang Z, Xu W, Wan F, et al. Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management. J Natl Cancer Center. 2025. https:\/\/doi.org\/10.1016\/j.jncc.2025.05.002.","journal-title":"J Natl Cancer Center"},{"issue":"10336","key":"7652_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1.","journal-title":"Lancet"},{"issue":"4","key":"7652_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(23)00063-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7652_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"32","key":"7652_CR8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"issue":"15","key":"7652_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"20","key":"7652_CR10","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7652_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"10","key":"7652_CR12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","volume":"23","author":"W Gu","year":"2022","unstructured":"Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(22)00507-1.","journal-title":"Lancet Oncol"},{"issue":"24","key":"7652_CR13","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.20.03661","volume":"39","author":"ZK Stadler","year":"2021","unstructured":"Stadler ZK, Maio A, Chakravarty D, et al. Therapeutic implications of germline testing in patients with advanced cancers. J Clin Oncol. 2021;39(24):2698\u2013709. https:\/\/doi.org\/10.1200\/JCO.20.03661.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7652_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"5","key":"7652_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9(5):635\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7762.","journal-title":"JAMA Oncol"},{"key":"7652_CR16","unstructured":"Spratt DE, Dorff T, Pessoa R. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 2.2025. J Natl Compr Canc Netw. Published online 2025."},{"issue":"6","key":"7652_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","volume":"73","author":"G Gravis","year":"2018","unstructured":"Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.001.","journal-title":"Eur Urol"},{"issue":"5","key":"7652_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34(5):477\u201385. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.009.","journal-title":"Ann Oncol"},{"issue":"24","key":"7652_CR19","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984\u201390. https:\/\/doi.org\/10.1200\/JCO.2006.06.4246.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7652_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Chen YH, Liu G, et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol. 2018;36(4):376\u201382. https:\/\/doi.org\/10.1200\/JCO.2017.75.3921.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7652_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11604-024-01646-9","volume":"43","author":"T Otani","year":"2025","unstructured":"Otani T, Nakamoto R, Umeoka S, Nakamoto Y. PSMA PET\/CT imaging and its application to prostate cancer treatment. Jpn J Radiol. 2025;43(1):1\u201312. https:\/\/doi.org\/10.1007\/s11604-024-01646-9.","journal-title":"Jpn J Radiol"},{"issue":"1","key":"7652_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","volume":"86","author":"WR Armstrong","year":"2024","unstructured":"Armstrong WR, Kishan AU, Booker KM, et al. Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774). Eur Urol. 2024;86(1):52\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2024.01.012.","journal-title":"Eur Urol"},{"key":"7652_CR23","doi-asserted-by":"publisher","unstructured":"MJ Karpinski K Rahbar M B\u00f6gemann et al 2025 Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study Eur Urol 495 https:\/\/doi.org\/10.1016\/j.eururo.2025.04.017","DOI":"10.1016\/j.eururo.2025.04.017"},{"key":"7652_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/17562872251321971","volume":"17","author":"F Matrone","year":"2025","unstructured":"Matrone F, Urso L, Girometti R, et al. The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est). Ther Adv Urol. 2025;17:17562872251321971. https:\/\/doi.org\/10.1177\/17562872251321971.","journal-title":"Ther Adv Urol"},{"issue":"15","key":"7652_CR25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/pros.24415","volume":"82","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tang Y, Gao X, et al. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil\u2013lymphocyte ratios, platelet\u2013lymphocyte ratios, and68 Ga-PSMA-PET-derived SUVmax values. Prostate. 2022;82(15):1415\u201321. https:\/\/doi.org\/10.1002\/pros.24415.","journal-title":"Prostate"},{"issue":"5","key":"7652_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2967\/jnumed.124.269189","volume":"66","author":"W Tang","year":"2025","unstructured":"Tang W, Qi L, Chen M, et al. Additive Value of [68 Ga]Ga-RM26 PET\/CT to [68 Ga]Ga-PSMA-617 PET\/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center. Phase II Study J Nucl Med. 2025;66(5):719\u201325. https:\/\/doi.org\/10.2967\/jnumed.124.269189.","journal-title":"Phase II Study J Nucl Med"},{"issue":"8","key":"7652_CR27","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00259-021-05636-1","volume":"49","author":"DX Qiu","year":"2022","unstructured":"Qiu DX, Li J, Zhang JW, et al. Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(8):2821\u201332. https:\/\/doi.org\/10.1007\/s00259-021-05636-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7652_CR28","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00259-024-06684-z","volume":"51","author":"Y Li","year":"2024","unstructured":"Li Y, Wang S, Zhao S, et al. Initial [18F]DCFPyL PET\/CT in treatment-na\u00efve prostate cancer: correlation with post-ADT PSA outcomes and recurrence. Eur J Nucl Med Mol Imaging. 2024;51(8):2458\u201366. https:\/\/doi.org\/10.1007\/s00259-024-06684-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7652_CR29","doi-asserted-by":"publisher","unstructured":"A Cimadamore C Boixareu A Sharp H Beltran JS De Bono 2025 Novel therapeutic strategies for metastatic prostate cancer care Eur Urol 5 https:\/\/doi.org\/10.1016\/j.eururo.2025.06.013","DOI":"10.1016\/j.eururo.2025.06.013"},{"key":"7652_CR30","unstructured":"An international prospective open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with SoC, versus SoC alone, in adult male patients with mHSPC (PSMAddition). Published online 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT04720157"},{"key":"7652_CR31","doi-asserted-by":"publisher","unstructured":"Agarwal N, Graff JN, Sandhu S, et al. Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J Clin Oncol. Published online June 10, 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5006","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07652-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:27Z","timestamp":1774401987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7652"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07652-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Xiangya Hospital of Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All individuals involved in this retrospective study signed written informed consent. The consent document clearly authorized both their participation in the study and the publication of their relevant PET\/CT images and clinical data, which have been properly de-identified to protect participant privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Publish"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study sponsors had no role in study design, data collection, data analyses, data interpretation, or manuscript writing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}